What if there is continued thrombocytopenia despite reaching complete remission (with incomplete marrow recovery)?
Such as the case in which a patient is unresponsive to steroids, IVIG, TPO-agonist, rituximab, splenectomy, and even fostamitinib.
Presuming strong indication for ASA - eg history of NSTEMI
e.g. DITP from eptifibatide after a cardiac intervention
IVIG, TPO, or other agents?
How often do you monitor ADAMTS-13 levels off therapy?
For example, do we prefer one regimen over the other in patients with a bleeding history or who have relapsed after a lengthy remission?
Does having a concurrent consumptive process e.g. DIC change your management?
Would you consider high-dose dexamethasone (deliberating adverse effects of antenatal steroids) or move to next-line therapies?